These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3836121)

  • 1. The effect of control on the pattern of utilization of cefotaxime, moxalactam and cefoperazone in a teaching hospital.
    Ma MY; Rho JP
    Drugs Exp Clin Res; 1985; 11(2):89-94. PubMed ID: 3836121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of formulary restriction of cefotaxime usage.
    DeVito JM; John JF
    Arch Intern Med; 1985 Jun; 145(6):1053-6. PubMed ID: 4004430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with the third generation cephalosporins, cefoperazone and cefotaxime: report.
    Reddy J
    N Z Med J; 1984 May; 97(755):293-6. PubMed ID: 6328390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The third generation cephems for surgical infections].
    Ishibiki K; Aikawa N
    Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1133-7. PubMed ID: 6095017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose cephalosporin prophylaxis of 929 surgical procedures in a prepaid group practice: a prospective, randomized comparison of cefoperazone and cefotaxime.
    Jones RN; Wojeski WV
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):323-34. PubMed ID: 3581737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new cephalosporins and penicillins.
    Weinstein AJ
    Compr Ther; 1982 Feb; 8(2):26-31. PubMed ID: 6279354
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between vitamin K1 2,3-epoxide and vitamin K1 in patients treated with N-methyl-thiotetrazole cephalosporins.
    Schäfer H; Matthias FR
    Thromb Res; 1992 Feb; 65(3):439-42. PubMed ID: 1631806
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative in vitro and in vivo activity of cefminox (MT-141), cefotaxime and cefoperazone against gram-negative bacteria.
    Watanabe T; Kazuno Y; Hirano F; Inouye S; Nishino T
    Drugs Exp Clin Res; 1985; 11(11):781-6. PubMed ID: 3841789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Third generation cephalosporins in severe infections in children].
    Havlík J; Maresová V
    Cesk Pediatr; 1985 Mar; 40(3):163-5. PubMed ID: 4005990
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams].
    Jarlier V; Bismuth R; Grosset J
    Pathol Biol (Paris); 1983 May; 31(5):336-42. PubMed ID: 6312393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain. A randomized pilot study].
    Schäfer H; Naber K; Adam D
    Arzneimittelforschung; 1989 Sep; 39(9):1156-62. PubMed ID: 2590268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals.
    Klesel N; Limbert M; Schrinner E; Seeger K; Seibert G; Winkler I
    Infection; 1984; 12(4):286-92. PubMed ID: 6092278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
    Kemmerich B; Lode H; Belmega G; Jendroschek T; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1983 Mar; 23(3):429-34. PubMed ID: 6303213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftriaxone--and more to come.
    Marks MI
    J Pediatr; 1983 Jul; 103(1):70-2. PubMed ID: 6306195
    [No Abstract]   [Full Text] [Related]  

  • 17. Third-generation cephalosporins for polymicrobial surgical sepsis.
    Stone HH; Strom PR; Fabian TC; Dunlop WE
    Arch Surg; 1983 Feb; 118(2):193-200. PubMed ID: 6295339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro combination effects of cefsulodin, moxalactam and cefoperazone with four aminoglycosides on nonfermenting nosocomial gram-negative bacteria.
    Daschner FD; Steffens A; Mählmann M; Metzger M
    Arzneimittelforschung; 1982; 32(5):531-3. PubMed ID: 6213241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of antimicrobial activity and stability to beta-lactamases of cefoperazone, cefotaxime, lamoxactam and ceftriaxon].
    Baumgärtner M; Grehn M; Wundt W
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):208-21. PubMed ID: 6289564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of two third-generation cephalosporins in prophylaxis for head and neck surgery.
    Johnson JT; Yu VL; Myers EN; Muder RR; Thearle PB; Diven WF
    Arch Otolaryngol; 1984 Apr; 110(4):224-7. PubMed ID: 6322734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.